Subsequent Events	9 Months Ended
Sep. 30, 2026
Subsequent Events [Abstract]
Subsequent Event	SUBSEQUENT EVENTS In October 2026 we signed an agreement with CMR Surgical, a global robotics company and maker of the Versius Plus surgical robot, to invest approximately $400 in cash in exchange for CMR Surgical's preferred equity. The agreement grants us exclusive U.S. distribution rights for the Versius portfolio and an exclusive option to acquire 100% of CMR Surgical's remaining outstanding equity in the future. The transaction is expected to close in the fourth quarter 2026, subject to regulatory approval and customary closing conditions. In October 2026 our Board of Directors approved an increase of $3,000 to our existing share repurchase program, bringing the total share repurchase authorization to $3,033. The manner, timing and amount of repurchases are determined by management based on an evaluation of market conditions, stock price, and other factors and are subject to regulatory considerations. Purchases may be made from time to time in the open market, in privately negotiated transactions or otherwise.

Subsequent Events

In October 2026 we signed an agreement with CMR Surgical, a

global robotics company and maker of the Versius Plus surgical

robot, to invest approximately $400 in cash in exchange for CMR

Surgical's preferred equity. The agreement grants us exclusive

U.S. distribution rights for the Versius portfolio and an exclusive

option to acquire 100% of CMR Surgical's remaining outstanding

equity in the future. The transaction is expected to close in the

fourth quarter 2026, subject to regulatory approval and customary

In October 2026 our Board of Directors approved an increase of

$3,000 to our existing share repurchase program, bringing the

total share repurchase authorization to $3,033. The manner,

timing and amount of repurchases are determined by

management based on an evaluation of market conditions, stock

price, and other factors and are subject to regulatory

considerations. Purchases may be made from time to time in the

open market, in privately negotiated transactions or otherwise.